Print this page
-
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab
Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small
Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1
Expression
Protocol: 032502Principal Investigator:
- Sivraj Muralikrishnan
Applicable Disease Sites: Lung -
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab
Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small
Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1
Expression
Protocol: 032502Principal Investigator:
- Sivraj Muralikrishnan
Applicable Disease Sites: Lung -
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Protocol: 032506Applicable Disease Sites: Lung
-
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Protocol: 032506Applicable Disease Sites: Lung
-
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer.
Protocol: 032507Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer.
Protocol: 032507Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Protocol: 032508Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Protocol: 032508Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Protocol: 032509Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Protocol: 032509Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors.
Protocol: 052509Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Esophagus
Lung
Other Digestive Organ
Pancreas
Thyroid -
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors.
Protocol: 052509Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Esophagus
Lung
Other Digestive Organ
Pancreas
Thyroid -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints
Lung -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints
Lung -
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB).
Protocol: 112505Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lung -
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB).
Protocol: 112505Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lung